Alisier Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 12 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 15.77%
(FY 2022)
- Profit 15.94%
(FY 2022)
- Ebitda 6483.83%
(FY 2022)
- Net Worth 69.54%
(FY 2022)
- Total Assets 13.63%
(FY 2022)
About Alisier Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Puneet Mahajan, Varesh Khanna, and Renu Sinha serve as directors at the Company.
- CIN/LLPIN
U24232HR2011PTC044698
- Company No.
044698
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Dec 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Alisier Drugs Private Limited offer?
Alisier Drugs Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibacterial Drugs, Third Party Manufacturing Consultancy, Pharmaceutical Third Party Manufacturing, Pharma Franchise, PCD Pharma Franchise, Pharmaceutical Marketing Services, Pharmaceutical Tablets, Antacid Drugs, Rabeprazole Tablets.
Who are the key members and board of directors at Alisier Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varesh Khanna  | Director | 28-Dec-2011 | Current |
| Puneet Mahajan | Director | 28-Dec-2011 | Current |
| Renu Sinha | Director | 01-Apr-2016 | Current |
Financial Performance of Alisier Drugs.
Alisier Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 15.77% increase. The company also saw a substantial improvement in profitability, with a 15.94% increase in profit. The company's net worth Soared by an impressive increase of 69.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alisier Drugs?
In 2022, Alisier Drugs had a promoter holding of 67.00% and a public holding of 33.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Alisier Drugs?
Unlock and access historical data on people associated with Alisier Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alisier Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alisier Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
